Immatics N.V. (IMTX) vs Sana Biotechnology (SANA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immatics N.V. (IMTX) has outperformed Sana Biotechnology (SANA) over the past year, losing 28.9% versus a loss of 38.4%. Over five years, IMTX leads with a -46.8% price change compared with -86.6% for SANA. Immatics N.V. is the larger company by market cap ($1.12 billion vs $835.2 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMTX | SANA |
|---|---|---|
| Share price | $7.37 | $2.79 |
| Market cap | $1.12B | $835.22M |
| 1-day change | -1.07% | +2.57% |
| YTD return | -29.81% | -31.45% |
| 1-year return | -28.93% | -38.41% |
| 5-year return | -46.79% | -86.58% |
| EPS (TTM) | $-1.87 | $-0.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.41 | $6.55 |
| 52-week low | $7.02 | $2.61 |
| Distance from 52-week high | -40.61% | -57.40% |
| Analyst consensus | none | none |
| Avg. price target upside | +139.21% | +202.15% |
| Average volume | 600.13K | 3.13M |
| Shares outstanding | 152.23M | 299.36M |
| Employees | 704 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immatics N.V.
IMTX stock →Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 704 employees
About Sana Biotechnology
SANA stock →Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
IMTX vs SANA FAQ
Which is bigger, Immatics N.V. or Sana Biotechnology?
Immatics N.V. (IMTX) is larger, with a market capitalization of $1.12B compared with $835.22M for Sana Biotechnology (SANA).
Which stock has performed better over the past year, IMTX or SANA?
IMTX returned -28.93% over the past 12 months, compared with -38.41% for SANA (price return, excluding dividends). Past performance does not predict future results.
Are Immatics N.V. and Sana Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.